Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Andrews

Showing results (21-30 of 364) with videos related to

Pageof 37
Sort By:
Vaccine|February 1, 2003
Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination eraCaroline Trotter, Ray Borrow, Nick Andrews, et al.
The Lancet. Infectious Diseases|November 1, 2020
Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UKShamez N Ladhani, Nick Andrews, Mary E Ramsay
Archives of Disease in Childhood|October 27, 2007
Idiopathic thrombocytopenic purpura and the second dose of MMRJulia Stowe, George Kafatos, Nick Andrews, et al.
Vaccine|August 31, 2010
Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United KingdomNick Andrews, Julia Stowe, Lesley Wise, et al.
Vaccine|May 17, 2005
Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagersJo Southern, Nick Andrews, Moya Burrage, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2018
The Use of Quasi-experimental Designs for Vaccine EvaluationJames A Lopez Bernal, Nick Andrews, Gayatri Amirthalingam
Human Vaccines|October 3, 2006
Bell's palsy and parenteral inactivated influenza vaccineJulia Stowe, Nick Andrews, Lesley Wise, et al.
Human Vaccines|February 22, 2007
Post-licensure safety of the meningococcal group C conjugate vaccineNick Andrews, Julia Stowe, Elizabeth Miller, et al.
The Journal of Infectious Diseases|December 15, 2010
Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in EnglandNick Andrews, Pauline Waight, Chee-Fu Yung, et al.
Plos One|March 2, 2013
Comparing the immunogenicity of AS03-adjuvanted 2009 pandemic H1N1 vaccine with clinical protection in priority risk groups in EnglandChee-Fu Yung, Nick Andrews, Katja Hoschler, et al.
Pageof 37

Showing results (21-30 of 364) with videos related to

Sort By:
Pageof 37
Vaccine|February 1, 2003
Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination eraCaroline Trotter, Ray Borrow, Nick Andrews, et al.
The Lancet. Infectious Diseases|November 1, 2020
Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UKShamez N Ladhani, Nick Andrews, Mary E Ramsay
Archives of Disease in Childhood|October 27, 2007
Idiopathic thrombocytopenic purpura and the second dose of MMRJulia Stowe, George Kafatos, Nick Andrews, et al.
Vaccine|August 31, 2010
Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United KingdomNick Andrews, Julia Stowe, Lesley Wise, et al.
Vaccine|May 17, 2005
Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagersJo Southern, Nick Andrews, Moya Burrage, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2018
The Use of Quasi-experimental Designs for Vaccine EvaluationJames A Lopez Bernal, Nick Andrews, Gayatri Amirthalingam
Human Vaccines|October 3, 2006
Bell's palsy and parenteral inactivated influenza vaccineJulia Stowe, Nick Andrews, Lesley Wise, et al.
Human Vaccines|February 22, 2007
Post-licensure safety of the meningococcal group C conjugate vaccineNick Andrews, Julia Stowe, Elizabeth Miller, et al.
The Journal of Infectious Diseases|December 15, 2010
Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in EnglandNick Andrews, Pauline Waight, Chee-Fu Yung, et al.
Plos One|March 2, 2013
Comparing the immunogenicity of AS03-adjuvanted 2009 pandemic H1N1 vaccine with clinical protection in priority risk groups in EnglandChee-Fu Yung, Nick Andrews, Katja Hoschler, et al.
Pageof 37